Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer
Bioequivalence study of SPARC147609
Ovarian Carcinoma
DRUG: SPARC147609|DRUG: Reference147609
90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-âˆž, of the test and reference product, 2 cycles
Treatment emergent adverse events, 2 cycles
Bioequivalence study of SPARC147609